Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Seagen Inc.
Regeneron Pharmaceuticals
BeOne Medicines
University Hospital, Lille
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Hoffmann-La Roche
PrECOG, LLC.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Hoffmann-La Roche
H. Lee Moffitt Cancer Center and Research Institute
Shanghai Junshi Bioscience Co., Ltd.
Mayo Clinic
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Genfleet Therapeutics (Shanghai) Inc.
BeiGene
Merck Sharp & Dohme LLC
BeiGene
University Health Network, Toronto
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.
University Hospital, Limoges
Merck Sharp & Dohme LLC
Centre Francois Baclesse
Samsung Medical Center
The First Hospital of Jilin University
Thomas Jefferson University
Seoul National University Hospital
Merck Sharp & Dohme LLC
EpicentRx, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Novartis
BeiGene
EMD Serono
Novartis
AstraZeneca
GlaxoSmithKline
Yonsei University
Radboud University Medical Center
Canadian Cancer Trials Group
Arcus Biosciences, Inc.